Generic drug impurities draft guidance
Executive Summary
FDA releases draft guidance entitled "ANDAs: Impurities in Drug Substances." The document, published in the Federal Register Jan. 31, is the first revision of the original 1999 guidance. The draft guidance suggests companies use stability studies, chemical development studies and routine batch analysis to test for impurities, which can be qualified in four ways...